Amgen Inc. (AMGN)
AMGN Stock Price Chart
Explore Amgen Inc. interactive price chart. Choose custom timeframes to analyze AMGN price movements and trends.
AMGN Company Profile
Discover essential business fundamentals and corporate details for Amgen Inc. (AMGN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
17 Jun 1983
Employees
28.00K
Website
https://www.amgen.comCEO
Robert A. Bradway
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
AMGN Financial Timeline
Browse a chronological timeline of Amgen Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 2 Feb 2026
Upcoming earnings on 29 Oct 2025
EPS estimate is $5.01, while revenue estimate is $8.98B.
Earnings released on 5 Aug 2025
EPS came in at $6.02 surpassing the estimated $5.28 by +14.02%, while revenue for the quarter reached $9.17B , beating expectations by +2.59%.
Dividend declared on 1 Aug 2025
A dividend of $2.38 per share was announced, adjusted to $2.38. The dividend was paid on 12 Sept 2025.
Earnings released on 1 May 2025
EPS came in at $4.90 surpassing the estimated $4.27 by +14.75%, while revenue for the quarter reached $8.15B , beating expectations by +1.14%.
Dividend declared on 4 Mar 2025
A dividend of $2.38 per share was announced, adjusted to $2.38. The dividend was paid on 6 Jun 2025.
Earnings released on 4 Feb 2025
EPS came in at $5.31 surpassing the estimated $5.04 by +5.36%, while revenue for the quarter reached $9.09B , beating expectations by +2.31%.
Dividend declared on 10 Dec 2024
A dividend of $2.38 per share was announced, adjusted to $2.38. The dividend was paid on 7 Mar 2025.
Earnings released on 30 Oct 2024
EPS came in at $5.58 surpassing the estimated $5.11 by +9.20%, while revenue for the quarter reached $8.50B , beating expectations by +0.06%.
Dividend declared on 25 Oct 2024
A dividend of $2.25 per share was announced, adjusted to $2.25. The dividend was paid on 9 Dec 2024.
Earnings released on 6 Aug 2024
EPS came in at $4.97 falling short of the estimated $4.98 by -0.20%, while revenue for the quarter reached $8.39B , beating expectations by +0.43%.
Dividend declared on 2 Aug 2024
A dividend of $2.25 per share was announced, adjusted to $2.25. The dividend was paid on 6 Sept 2024.
Earnings released on 2 May 2024
EPS came in at $3.96 surpassing the estimated $3.88 by +2.06%, while revenue for the quarter reached $7.45B , missing expectations by -0.06%.
Dividend declared on 6 Mar 2024
A dividend of $2.25 per share was announced, adjusted to $2.25. The dividend was paid on 7 Jun 2024.
Earnings released on 6 Feb 2024
EPS came in at $4.71 surpassing the estimated $4.59 by +2.61%, while revenue for the quarter reached $8.20B , beating expectations by +0.86%.
Dividend declared on 12 Dec 2023
A dividend of $2.25 per share was announced, adjusted to $2.25. The dividend was paid on 7 Mar 2024.
Earnings released on 31 Oct 2023
EPS came in at $4.96 surpassing the estimated $4.65 by +6.67%, while revenue for the quarter reached $6.90B , beating expectations by +4.33%.
Dividend declared on 24 Oct 2023
A dividend of $2.13 per share was announced, adjusted to $2.13. The dividend was paid on 8 Dec 2023.
Earnings released on 3 Aug 2023
EPS came in at $5.00 surpassing the estimated $4.44 by +12.61%, while revenue for the quarter reached $6.99B , beating expectations by +4.64%.
Dividend declared on 1 Aug 2023
A dividend of $2.13 per share was announced, adjusted to $2.13. The dividend was paid on 8 Sept 2023.
Earnings released on 27 Apr 2023
EPS came in at $3.98 surpassing the estimated $3.85 by +3.38%, while revenue for the quarter reached $6.11B , missing expectations by -8.17%.
Dividend declared on 7 Mar 2023
A dividend of $2.13 per share was announced, adjusted to $2.13. The dividend was paid on 8 Jun 2023.
Earnings released on 31 Jan 2023
EPS came in at $4.09 surpassing the estimated $4.04 by +1.24%, while revenue for the quarter reached $6.84B , beating expectations by +1.41%.
Dividend declared on 12 Dec 2022
A dividend of $2.13 per share was announced, adjusted to $2.13. The dividend was paid on 8 Mar 2023.
Earnings released on 3 Nov 2022
EPS came in at $4.70 surpassing the estimated $4.44 by +5.86%, while revenue for the quarter reached $6.65B , beating expectations by +1.34%.
Dividend declared on 28 Oct 2022
A dividend of $1.94 per share was announced, adjusted to $1.94. The dividend was paid on 8 Dec 2022.
Earnings released on 4 Aug 2022
EPS came in at $4.65 surpassing the estimated $4.40 by +5.68%, while revenue for the quarter reached $6.59B , beating expectations by +0.96%.
Dividend declared on 3 Aug 2022
A dividend of $1.94 per share was announced, adjusted to $1.94. The dividend was paid on 8 Sept 2022.
Earnings released on 27 Apr 2022
EPS came in at $4.25 surpassing the estimated $4.22 by +0.71%, while revenue for the quarter reached $6.24B , beating expectations by +2.78%.
Dividend declared on 2 Mar 2022
A dividend of $1.94 per share was announced, adjusted to $1.94. The dividend was paid on 8 Jun 2022.
Earnings released on 7 Feb 2022
EPS came in at $4.36 surpassing the estimated $4.08 by +6.86%, while revenue for the quarter reached $6.85B , missing expectations by -0.34%.
Dividend declared on 3 Dec 2021
A dividend of $1.94 per share was announced, adjusted to $1.94. The dividend was paid on 8 Mar 2022.
Earnings released on 2 Nov 2021
EPS came in at $4.67 surpassing the estimated $4.22 by +10.66%, while revenue for the quarter reached $6.71B , missing expectations by -0.08%.
Dividend declared on 21 Oct 2021
A dividend of $1.76 per share was announced, adjusted to $1.76. The dividend was paid on 8 Dec 2021.
Earnings released on 3 Aug 2021
EPS came in at $4.38 surpassing the estimated $4.13 by +6.05%, while revenue for the quarter reached $6.53B , beating expectations by +1.18%.
Dividend declared on 30 Jul 2021
A dividend of $1.76 per share was announced, adjusted to $1.76. The dividend was paid on 8 Sept 2021.
Earnings released on 27 Apr 2021
EPS came in at $3.70 falling short of the estimated $4.05 by -8.64%, while revenue for the quarter reached $5.90B , missing expectations by -6.12%.
Dividend declared on 3 Mar 2021
A dividend of $1.76 per share was announced, adjusted to $1.76. The dividend was paid on 8 Jun 2021.
Earnings released on 2 Feb 2021
EPS came in at $3.81 surpassing the estimated $3.36 by +13.39%, while revenue for the quarter reached $6.63B , beating expectations by +14.14%.
Dividend declared on 16 Dec 2020
A dividend of $1.76 per share was announced, adjusted to $1.76. The dividend was paid on 8 Mar 2021.
Earnings released on 28 Oct 2020
EPS came in at $4.37 surpassing the estimated $3.81 by +14.70%, while revenue for the quarter reached $6.42B , beating expectations by +14.70%.
Dividend declared on 21 Oct 2020
A dividend of $1.60 per share was announced, adjusted to $1.60. The dividend was paid on 8 Dec 2020.
AMGN Stock Performance
Access detailed AMGN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.